Helen Torley

Companies

• Halozyme TherapeuticsBoard member Jan 8, 2014 to now¹
• Halozyme TherapeuticsChief executive officer Jan 8, 2014 to now¹
• Halozyme TherapeuticsPresident Jan 8, 2014 to now¹
• Quest DiagnosticsBoard member May 17, 2018 to May 25, 2021²
• Onyx PharmaceuticalsChief Opertaing Officer Aug 31, 2011 to Oct 3, 2013³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• HTHalozyme Therapeutics HALO767,780 shares⁴$94.4M at $122.96Sep 11, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

• Sep 11, 2026Sold 4,508 shares at $107.55 of Halozyme Therapeutics⁴
• Sep 11, 2026Sold 15,492 shares at $107.15 of Halozyme Therapeutics⁴
• Sep 11, 2026Exercised options 20,000 shares at $18.41 of Halozyme Therapeutics⁴
• Sep 10, 2026Sold 5,412 shares at $107.58 of Halozyme Therapeutics⁴
• Sep 10, 2026Sold 14,588 shares at $107.01 of Halozyme Therapeutics⁴
• Sep 10, 2026Exercised options 20,000 shares at $18.41 of Halozyme Therapeutics⁴
• Sep 9, 2026Sold 100 shares at $108.67 of Halozyme Therapeutics⁴
• Sep 9, 2026Sold 6,596 shares at $107.82 of Halozyme Therapeutics⁴
• Sep 9, 2026Sold 13,304 shares at $107.22 of Halozyme Therapeutics⁴
• Sep 9, 2026Exercised options 20,000 shares at $18.41 of Halozyme Therapeutics⁴
• Aug 19, 2026Sold 3,200 shares at $107.77 of Halozyme Therapeutics⁵
• Aug 19, 2026Sold 9,600 shares at $107.22 of Halozyme Therapeutics⁵
• Aug 19, 2026Sold 7,200 shares at $106.36 of Halozyme Therapeutics⁵
• Aug 19, 2026Exercised options 20,000 shares at $18.41 of Halozyme Therapeutics⁵
• Aug 18, 2026Sold 9,400 shares at $104.87 of Halozyme Therapeutics⁵
• Aug 18, 2026Sold 4,897 shares at $104.11 of Halozyme Therapeutics⁵
• Aug 18, 2026Sold 5,703 shares at $103.08 of Halozyme Therapeutics⁵
• Aug 18, 2026Exercised options 20,000 shares at $18.41 of Halozyme Therapeutics⁵
• Aug 17, 2026Sold 7,500 shares at $103.48 of Halozyme Therapeutics⁵
• Aug 17, 2026Sold 9,000 shares at $102.55 of Halozyme Therapeutics⁵
• Aug 17, 2026Sold 2,100 shares at $101.77 of Halozyme Therapeutics⁵
• Aug 17, 2026Sold 500 shares at $100.46 of Halozyme Therapeutics⁵
• Aug 17, 2026Sold 900 shares at $98.96 of Halozyme Therapeutics⁵
• Aug 17, 2026Exercised options 20,000 shares at $18.41 of Halozyme Therapeutics⁵
• Jul 8, 2026Sold 1,035 shares at $80.19 of Halozyme Therapeutics⁶